Geron (GERN) Shares Outstanding (2010 - 2026)
Geron's (GERN) quarterly Shares Outstanding (Entity) came in at $642.5 million in Q2 2026, up 0.7% year-over-year from $638.0 million in Q2 2025, and little changed quarter-over-quarter from $639.9 million in Q4 2025.
Analysis
Geron (GERN) Shares Outstanding (2010 - 2026) Analysis & Trends
Geron has disclosed Shares Outstanding (Entity) across 17 years of filings, most recently posting $642.5 million for Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 0.7% year-over-year to $642.5 million; the TTM figure through Jun 2026 stood at $642.5 million (up 0.7% YoY), while the FY2025 annual figure was $639.9 million, up 5.52% from the prior year.
- Shares Outstanding (Entity) came in at $642.5 million for Q2 2026 at Geron, roughly flat from $639.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $642.5 million in Q2 2026 to a low of $377.4 million in Q1 2022.
- Average Shares Outstanding (Entity) over 5 years is $544.1 million, with a median of $593.1 million recorded in 2024.
- Year-over-year, Shares Outstanding (Entity) soared 42.45% in 2023 and grew 0.7% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $390.3 million in 2022, then jumped by 39.63% to $544.9 million in 2023, then gained by 11.28% to $606.4 million in 2024, then advanced by 5.52% to $639.9 million in 2025, then increased by 0.41% to $642.5 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $642.5 million in Q2 2026, $639.9 million in Q4 2025, and $638.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 670.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 670.04 Mn |
| Mar 31, 2026 | 666.66 Mn |
| Dec 31, 2025 | 666.66 Mn |
| Sep 30, 2025 | 667.10 Mn |
| Jun 30, 2025 | 666.17 Mn |
| Mar 31, 2025 | 665.91 Mn |
| Dec 31, 2024 | 646.03 Mn |
| Sep 30, 2024 | 662.16 Mn |
| Jun 30, 2024 | 653.90 Mn |
| Mar 31, 2024 | 603.49 Mn |
| Dec 31, 2023 | 570.65 Mn |
| Sep 30, 2023 | 579.51 Mn |
| Jun 30, 2023 | 547.28 Mn |
| Mar 31, 2023 | 544.46 Mn |
| Dec 31, 2022 | 380.78 Mn |
| Sep 30, 2022 | 405.24 Mn |
| Jun 30, 2022 | 403.87 Mn |
| Mar 31, 2022 | 332.07 Mn |
| Dec 31, 2021 | 327.63 Mn |
| Sep 30, 2021 | 328.93 Mn |